Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus

Journal of Clinical Pharmacology

Volumn 37, Issue 2, 1997, Pages 155-159

  Martin, David E ^a   DeCherney, G Stephen ^b   Ilson, Bernard E ^a   Jones, Beverly A ^a   Boike, Steven C ^a   Freed, Martin I ^a   Jorkasky, Diane K ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b MEDICAL CENTER OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPROSARTAN; GLIBENCLAMIDE;

ADULT; AGED; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MIXTURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT PLANNING;

EID: 0030939617     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04774.x     Document Type: Article

References (15)

1. Duncia JV, Chiu AT, Carini, Gregory JB, Johnson AL, Price WA, et al: The discovery of potent non-peptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Chem 1990;33:1312-1329.
2. Weinstock J, Keenan RM, Samanen J, Hempel J, Finkelstein JA, Franz RG, et al: 1-(carboxy-benzyl)imidaxole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 1991;34:1514-1517.
3. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, et al: Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260:175-181.
4. Brooks DP, Fredrickson TA, Weinstock J, Ruffolo RR, Edwards RM, Gellai M: Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Arch Pharmacol 1992;345:673-678.
5. Punzi HA: Hypertension and concomitant diseases. In, Flamenbaum W (ed): Hypertension. Mount Kisco, New York: Futura Publishing Co, Inc, 1989;257-258.
6. Krolewski AS, Warram JH: Epidemiology of diabetes mellitus. In, Marble A, Krall LP, Bradley RF, Christlieb AR, Soeldner JS (eds.): Joslin's Diabetes Mellitus. Philadelphia: Lea & Febiger, 1985;12-42.
7. Kuhn T: The second generation oral sulfonylureas: glyburide and glipizide. Am Pharm 1988;10(suppl NS2):55-61.
8. Prendergast BD: Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm 1984;3:473-485.
9. Upjohn Company micronase tablets. In, Physicians' Desk Reference. Fiftieth Edition. New Jersey: Medical Economics Company, 1996;2623-2625.
10. Hansten PD: Antidiabetic drug interactions. In, Drug Interactions. Fifth edition. Philadelphia: Lea & Febiger, 1985;150-169.
11. Ahmad S: Gemfibrozil: interaction with glyburide. South Med J 1991;84:102.
12. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
13. Schuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
14. Kaplan NM: An overview of hypertension: the individual and the public challenge. In, Clinical Hypertension. Third edition. Baltimore: Williams & Wilkins, 1982:26-27.
15. Fraser DG, Ludden TM, Evens RP, Sutherland EW III: In vivo displacement of phenytoin from plasma proteins with salicylates. Clin Pharmacol Ther 1979;25:226.